Document:

EX-10.39

 Exhibit 10.39 
 CYTOKINETICS, INCORPORATED 
 EXECUTIVE EMPLOYMENT AGREEMENT

 This Executive Employment Agreement (this “Agreement”) is made and entered into by and between
            (“Executive”) and Cytokinetics, Incorporated, a Delaware corporation (the “Company”), effective as of
            (the “Effective Date”). 

BACKGROUND 
 A. It is expected that the Company from time to time will consider a possible acquisition by another company or other change of control. The Board of Directors of the Company (the
“Board”) recognizes that such consideration can be a distraction to Executive and can cause Executive to consider alternative employment opportunities. The Board has determined that it is in the Company’s and its
stockholders’ best interests to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of a change of control of the Company. 

B. The Board believes that it is in the Company’s and its stockholders’ best interests to provide Executive with an incentive
to continue his or her employment and to motivate Executive to maximize the value of the Company upon a change of control for the benefit of its stockholders. 
 C. The Board believes that it is in the Company’s and its stockholders’ best interests to provide Executive with certain severance benefits upon Executive’s termination of employment
following a change of control. These benefits will provide Executive with enhanced financial security and incentive and encouragement to remain with the Company notwithstanding a possible change of control. 

AGREEMENT 
 The parties hereby agree as follows: 
 1. Definition of Terms. The
following capitalized terms referred to in this Agreement will have the following meanings: 
 (a) “Arbitration
Agreement” means the Arbitration Agreement by and between the Company and Executive, as may be amended from time to time, and any successor agreement thereto. 
 (b) “Benefit Plans” means plans, policies or arrangements that the Company sponsors (or participates in) and that immediately prior to Executive’s termination of employment provide
Executive and/or Executive’s eligible dependents with medical, dental, 

 
and/or vision benefits. Benefit Plans do not include any other type of benefit (including, but not by way of limitation, disability, life insurance or retirement benefits). A requirement that the
Company provide Executive and Executive’s eligible dependents with coverage under the Benefit Plans will not be satisfied unless the coverage is no less favorable, taken as a whole, than that provided to other Officers at the same time during
the period Executive is entitled to receive severance pursuant to this Agreement. 
 (c) “Cause” means any of
the following: 
 (i) Executive’s failure to substantially perform Executive’s duties with the Company (other than
due to Executive’s incapacity as a result of physical or mental illness for a period not to exceed 90 days); 
 (ii)
Executive’s engaging in conduct which is materially injurious to the Company, its business or reputation, or which constitutes gross misconduct; 
 (iii) Executive’s material breach of this Agreement, the Invention Agreement or any other agreements between Executive and the Company; 

(iv) Executive’s material breach, or act or omission in material contravention of, the Company’s policies adopted by the Board
or any committee thereof, including, without limitation, the Company’s Code of Ethics, Insider Trading Compliance Program, Disclosure Process and Procedures and Corporate Governance Guidelines; 

(v) Executive’s conviction for or admission or plea of no contest with respect to a felony; or 

(vi) Executive’s act of fraud against the Company, misappropriation of material property belonging to the Company, or act of
violence against an officer, director, employee, contractor, agent or representative of the Company; 
 provided, however, that
if any of the foregoing events in (i), (iii) or (iv) are reasonably capable of being cured, such event will only be deemed to be “Cause” if the Company has provided written notice to Executive describing the nature of such event,
and Executive fails to cure such event to the Company’s reasonable satisfaction within thirty (30) days of his or her receipt of such notice. 
 (d) “Change of Control” means the occurrence of any of the following: 
 (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3
under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; or 

(ii) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation that
would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either 

 
by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by the voting securities of
the Company or such surviving entity outstanding immediately after such merger or consolidation; 
 (iii) The consummation of
the sale, lease or other disposition by the Company of all or substantially all the Company’s assets; or 
 (iv) Any
action or event occurring within a two-year period, as a result of which fewer than a majority of the directors of the Company are Incumbent Directors. “Incumbent Director” means a director of
the Board who either (A) is a director of the Board as of the Effective Date, or (B) is elected, or nominated for election, to the Board with the affirmative votes of at least a majority of those directors whose election or nomination did
not occur in connection with any transaction described in subsection (d)(i), (d)(ii) or (d)(iii) above. 
 (e)
“Code” means the Internal Revenue Code of 1986, as amended. 
 (f) “Disability” means that
Executive has been unable to perform his or her Company duties as the result of his or her incapacity due to physical or mental illness, and such inability, at least twenty-six (26) weeks after its commencement, is determined to be total and
permanent by a physician selected by the Company or its insurers and reasonably acceptable to Executive or Executive’s legal representative. Termination resulting from Disability may only be effected after at least thirty (30) days’
written notice by the Company of its intention to terminate Executive’s employment. If Executive resumes the performance of substantially all of his or her duties hereunder before the termination of his or her employment becomes effective, the
notice of intent to terminate will automatically be deemed to have been revoked. 
 (g) “Exchange Act” means
the Securities Exchange Act of 1934, as amended. 
 (h) “Good Reason” means the occurrence of any one or more
of the following conditions, unless agreed to by Executive in writing or as set forth below: 
  

	 	(i)	A material diminution in the Executive’s base compensation; 

  

	 	(ii)	A material diminution in the Executive’s authority, duties or responsibilities; 

 

	 	(iii)	A material diminution in the authority, duties, or responsibilities of the supervisor to whom the Executive is required to report, e.g., a requirement that the
Executive report to a corporate officer or employee instead of reporting directly to the board of directors of a corporation (or similar governing body with respect to an entity other than a corporation); 

 

	 	(iv)	A material diminution in the budget over which the Executive retains authority prior to such change; 

 

	 	(v)	 A material change in the geographic location at which the Executive must perform the services (i.e., the relocation of

	 	
Executive’s place of employment to a location that increases Executive’s one-way commute by more than 50 miles from the Company’s office location at the time of the Change of
Control); or 

  

	 	(vi)	Any other action or inaction that constitutes a material breach by the Company or a successor entity of this Agreement; 

provided that, to establish “Good Reason,” (A) Executive must give written notice of the occurrence of the applicable event to the Company
within ninety (90) days after the initial existence of the condition; (B) the Company does not reasonably cure the event within thirty (30) days from the Company’s receipt of such notice; and (C) Executive resigns for Good
Reason and his or her Separation from Service occurs within forty-five (45) days after the end of the notice period. 
 (i)
“Invention Agreement” means the Proprietary Information and Invention Assignment Agreement by and between the Company and Executive, as may be amended from time to time, and any successor agreement thereto. 

(j) “Officer” means an “officer” of the Company, as defined in Rule 16a-1(f) under the Exchange Act.

 (k) “Section 409A” means Section 409A of the Code and the final regulations and any guidance
promulgated thereunder. 
 (l) “Section 409A Limit” means the limit necessary for compliance with Treasury
Regulation 1.409A-1(b)(9)(iii), which, as of the date hereof, is two (2) times the lesser of: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Company’s taxable year preceding
the Company’s taxable year of Executive’s termination of employment as determined under Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; and (ii) the maximum amount
that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Executive’s employment is terminated. 
 (m) “Separation from Service” means a “separation from service” within the meaning of Treasury Regulation 1.409A-1(h), without regard to any alternative definition thereunder.

 (n) “Treasury Regulations” means Title 26 of the U.S. Code of Federal Regulations. 

2. Term of Agreement. This Agreement will terminate upon the date that all of the obligations of the parties hereto with respect
to this Agreement have been satisfied. 
 3. At-Will Employment. The Company and Executive acknowledge that
Executive’s employment is and will continue to be at-will, as defined under applicable law. If Executive’s employment terminates for any reason, including (without limitation) any termination prior to a Change of Control, Executive will
not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement or by law. 

 4. Duties and Scope of Employment. 

(a) Positions and Duties. As of the Effective Date, Executive will serve as
                                        of the
Company. Executive will render such business and professional services in the performance of his or her duties, consistent with Executive’s position within the Company, as will reasonably be assigned to him or her by the Board. 

(b) Obligations. While Executive is employed by the Company, Executive will (i) perform his or her duties faithfully and to
the best of his or her ability and will devote his or her full business efforts and time to the Company, and (ii) not engage in any other employment, occupation or consulting activity for any material direct or indirect remuneration without the
Board’s prior approval. 
 5. Compensation. 

(a) Base Salary. While Executive is employed by the Company, the Company will pay Executive an annual salary as determined in the
discretion of the Board or any committee thereof. The base salary will be paid periodically in accordance with the Company’s normal payroll practices and will be subject to the usual, required withholding. Executive’s salary will be
subject to review and adjustments will be made based upon the Company’s normal performance review practices. 
 (b) Performance Bonus. Executive will be eligible to receive an annual bonus and other bonuses, less applicable withholding taxes, as determined by the Board or any committee thereof in the
Board’s or such committee’s sole discretion. Any earned bonus is payable no later than
March 15th of the year following the year in which it
is no longer subject to a substantial risk of forfeiture. 
 (c) Equity Compensation. Executive will be eligible to
receive stock option grants, and other equity compensation awards, as determined by the Board or any committee thereof in the Board’s or such committee’s sole discretion. 

6. Employee Benefits. While Executive is an employee of the Company, Executive will be entitled to participate in the Benefit
Plans currently and hereafter maintained by the Company of general applicability to other Officers, subject to any eligibility or other terms of such Benefit Plans. The Company reserves the right to cancel or change the Benefit Plans it offers to
its employees at any time. 
 7. Vacation. Executive will be entitled to vacation in accordance with the Company’s
vacation policy, with the timing and duration of specific vacations mutually and reasonably agreed to by the parties hereto. 

8. Expenses. The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in
the furtherance of or in connection with the performance of Executive’s duties as an employee of the Company, in accordance with the Company’s expense reimbursement policy as in effect from time to time. 

 9. Severance Benefits. 

(a) Involuntary Termination Following a Change of Control. If on or within eighteen (18) months following a Change of
Control: 
  

	 	(X)	(i) Executive terminates his or her employment with the Company (or any parent or subsidiary of the Company) for Good Reason, or 

 

	 	(ii)	the Company (or any parent or subsidiary of the Company) terminates Executive’s employment for other than Cause (and other than as a result of Executive’s
death or Disability); 

  

	 	(Y)	Executive delivers to the Company an effective, general release of all claims in favor of the Company, in a form reasonably acceptable to the Company, which release is
effective not later than fifty-two (52) days following the date of Executive’s Separation from Service; and 

  

	 	(Z)	provided that Executive’s termination constitutes a Separation from Service; 

 then Executive will receive the following severance from the Company (the “Severance Benefits”): 

(i) Severance Payment. Executive will be entitled to (A) receive continuing payments of severance pay
(less applicable withholding taxes) at a rate equal to Executive’s base salary rate, as then in effect (but ignoring any reduction in base salary rate that forms the basis for Good Reason), for a period of eighteen (18) months following
Executive’s Separation from Service; and (B) a lump-sum payment on the fifty-third (53rd) day following the Separation from Service equal to 100% of Executive’s target annual bonus as of the date of such termination. 

(ii) Equity Awards. All of Executive’s then-outstanding equity awards, including, without limitation, stock options,
restricted stock awards and restricted stock unit awards, will immediately vest on the date of the Separation from Service and, if applicable, become exercisable, as to 100% of such award. 

(iii) Continued Employee Benefits. If Executive is participating in the Company’s Benefit Plans at the time of his or her
Separation from Service and Executive timely elects continued coverage under Title X of the Consolidated Budget Reconciliation Act of 1985, as amended (“COBRA”), Executive will receive Company-paid coverage for Executive and
Executive’s eligible dependents under the Company’s Benefit Plans from the date of Executive’s Separation from Service until the earliest of (A) eighteen (18) months following Executive’s Separation from Service,
(B) the expiration of Executive’s eligibility for the continuation coverage under COBRA, or (C) such time as Executive secures employment with benefits substantially similar, taken as a whole, to those provided under the COBRA
coverage at that time (the period from the date of Executive’s Separation from Service through the earliest of (A) through (C), the “COBRA Payment Period”). Notwithstanding the foregoing, if at any time the

 
Company determines, in its sole discretion, that the payment of the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute
or regulation of similar effect (including, without limitation, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums, the Company will
instead pay Executive, on the first day of each month of the remainder of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings and deductions. If Executive becomes
eligible for coverage under another employer’s group health plan or otherwise ceases to be eligible for COBRA during the Severance Period, Executive must immediately notify the Company of such event, and all payments and obligations under this
Section will cease. 
 (b) Timing of Severance Payments. 

(i) General. No Severance Benefits shall be paid or provided until the release described in
Section 9(a)(Y) becomes effective. Any Severance Benefits to which Executive otherwise would have been entitled under Section 9(a) during the fifty-two (52) day period referred to in Section 9(a)(Y) shall be paid or provided, as
applicable, by the Company to Executive in full arrears on the fifty-third (53rd) day following Executive’s Separation from Service in accordance with Section 409A. Any other Severance Benefits will be paid or provided, as applicable, by the Company to the Executive in
accordance with normal payroll policies as provided in Section 9(a). If Executive should die before all amounts have been paid, such unpaid amounts will be paid in a lump-sum payment to Executive’s designated beneficiary, if living, or
otherwise to the personal representative of Executive’s estate. 
 (ii) Section 409A. 

(A) Amounts paid under this Agreement are intended to satisfy the requirements of the “short-term deferral” rule set forth in
Treasury Regulation 1.409A-1(b)(4) of the Treasury Regulations to the greatest extent possible, and to the extent not so exempt, such amounts are intended to be exempt under Treasury Regulation 1.409A-1(b)(9). 

(B) Notwithstanding anything to the contrary in this Agreement, if Executive is a “specified employee” within the meaning of
Section 409A at the time of Executive’s termination (other than due to death), and if any of the severance payable to Executive pursuant to this Agreement, together with any other severance payments or separation benefits, are considered
“deferred compensation” under Section 409A (together, the “Deferred Compensation Separation Benefits”), any such Deferred Compensation Separation Benefits that would otherwise be payable within the first six
(6) months following Executive’s termination of employment will not be paid as scheduled, and will instead become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the
date of Executive’s Separation from Service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable thereafter in accordance with the original payment schedule applicable to each payment or benefit. Notwithstanding
anything herein to the contrary, if Executive dies following his or her Separation from Service but prior to the six (6) month anniversary of his or her termination, then any payments delayed in accordance with this paragraph will be payable in
a lump sum as soon as administratively practicable after the date of 

 
Executive’s death and all other Deferred Compensation Separation Benefits will be payable thereafter in accordance with the original payment schedule applicable to each payment or benefit.
Each payment and benefit payable under this Agreement is intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 
 (C) The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the
additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. 
 (c) Voluntary
Resignation; Termination for Cause. If Executive’s employment terminates within eighteen (18) months following a Change of Control (i) voluntarily by Executive other than for Good Reason or (ii) for Cause by the Company, then
Executive will not be entitled to receive severance or other benefits, except for those as may then be established under the Company’s then existing severance plans and Benefits Plans or pursuant to other written agreements with the Company.

 (d) Disability; Death. If the Company terminates Executive’s employment as a result of Executive’s
Disability, or Executive’s employment terminates due to his or her death, then Executive will not be entitled to receive severance or other benefits, except for those as may then be established under the Company’s then existing written
severance and Benefits Plans or pursuant to other written agreements with the Company. 
 (e) Termination Apart from Change
of Control. If Executive’s employment terminates for any reason, either prior to the occurrence of a Change of Control or after the eighteen (18) month period following a Change of Control, then Executive will be entitled to receive
severance and any other benefits only as may then be established under the Company’s existing written severance plans and Benefits Plans, if any, or pursuant to any other written agreements with the Company. 

(f) Exclusive Remedy. If Executive’s employment terminates within eighteen (18) months following a Change of Control,
the provisions of this Section 9 are intended to be and are exclusive and in lieu of any other rights or remedies to which Executive or the Company may otherwise be entitled, whether at law, tort or contract, in equity, or under this Agreement.
Executive will be entitled to no benefits, compensation or other payments or rights upon termination of employment following a Change of Control other than those benefits expressly set forth in this Section 9. 

10. Conditional Nature of Severance Payments. 
 (a) Invention Agreement. If Executive is in material breach of the Invention Agreement, including, without limitation, Executive’s obligations of confidentiality and of non-solicitation
contained in the Invention Agreement, then upon such breach by Executive: (i) Executive will refund to the Company all cash paid to Executive pursuant to Section 9 of this Agreement; and (ii) all severance benefits pursuant to this
Agreement will immediately cease. 
 (b) Non-Competition. Executive acknowledges that the nature of the Company’s
business is such that if Executive were to become employed by, or substantially 

 
involved in, the business of a competitor of the Company during the eighteen (18) months following the termination of Executive’s employment, it would be very difficult for Executive
not to rely on or use the Company’s trade secrets and confidential information. Accordingly, to avoid the inevitable disclosure of the Company’s trade secrets and confidential information, Executive agrees and acknowledges that
Executive’s right to receive the severance payments set forth in this Agreement (to the extent Executive is otherwise entitled to such payments and to the extent permitted by law) will be conditioned upon Executive not directly or indirectly
engaging in (whether as an employee, consultant, agent, proprietor, principal, partner, stockholder, corporate officer, director or otherwise), nor having any ownership interest in or participating in the financing, operation, management or control
of, any person, firm, corporation or business that directly competes with the Company or is a customer of the Company during such 18-month period. Notwithstanding the foregoing, Executive may own, directly or indirectly, up to 2% of the capital
stock of a company that directly competes with the Company, provided such capital stock is traded on a national securities exchange or through the automated quotation system of a registered securities association. Upon any breach of this Section and
to the extent permitted by law, (i) Executive will refund to the Company all cash paid to Executive pursuant to Section 9 of this Agreement; and (ii) all severance payments pursuant to this Agreement will immediately cease.

 11. Limitation on Payments. If the severance, payments and other benefits provided for in this Agreement or otherwise
payable to Executive (a “Payment”) would (i) constitute “parachute payments” within the meaning of Section 280G of the Code, and (ii) but for this Section 11, would be subject to the excise tax imposed
by Section 4999 of the Code (the “Excise Tax”), then Executive’s severance benefits will be equal to the Reduced Amount. The “Reduced Amount” will be either: 

(a) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or 

(b) the largest portion, up to and including the total, of the Payment, whichever amount ((a) or (b)), after taking into account all
applicable federal, state, provincial, foreign, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greatest economic
benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. 
 If a reduction in payments or benefits
constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of stock awards
other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits paid to Executive. Within any such category of Payments (that is, (1), (2), (3) or (4)), a reduction will occur
first with respect to amounts that are not “deferred compensation” within the meaning of Section 409A of the Code and then with respect to amounts that are. In the event that acceleration of vesting of stock award compensation is to
be reduced, the acceleration of vesting will be cancelled in the reverse order of the date of grant of Executive’s applicable type of stock award (i.e., earliest granted stock awards are cancelled last). 

 12. Invention and Arbitration Agreements. Executive agrees and acknowledges that the
Invention Agreement and the Arbitration Agreement will continue in full force and effect and Executive agrees to abide by the terms thereof. 
 13. Successors. 
 (a) The Company’s Successors. Any successor
to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets will assume the obligations and rights under this Agreement
and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the
term “Company” will include any successor to the Company’s business and/or assets that executes and delivers an agreement setting forth the assumption described above or that becomes bound by this Agreement by operation of law.

 (b) Executive’s Successors. This Agreement and all rights of Executive hereunder will inure to the benefit of,
and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. 
 14. Notice. 
 (a) General. Notices and all other communications
contemplated by this Agreement will be in writing and will be deemed to have been duly given when personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of Executive,
mailed notices will be addressed to him or her at the home address which he or she most recently communicated to the Company in writing. In the case of the Company, mailed notices will be addressed to its corporate headquarters, and all notices will
be directed to the attention of its Chief Executive Officer (or, if Executive holds the position of Chief Executive Officer, then to the Company’s General Counsel). 
 (b) Notice of Termination. Any termination by the Company for Cause or by Executive for Good Reason or as a result of a voluntary resignation will be communicated by a notice of termination to the
other party hereto given in accordance with Section 14(a). Such notice will indicate the specific termination provision in this Agreement relied upon, will set forth in reasonable detail the facts and circumstances claimed to provide a basis
for termination under the provision so indicated, and will specify the termination date (which will be not more than thirty (30) days after the giving of such notice). 
 15. Miscellaneous Provisions. 
 (a) No Duty to Mitigate. Executive
will not be required to mitigate the amount of any payment contemplated by this Agreement, nor, except as otherwise contemplated in this Agreement, will any such payment be reduced by any earnings that Executive may receive from any other source.

 (b) Waiver and Modification. No provision of this Agreement will be modified, waived or discharged unless the
modification, waiver or discharge is agreed to in 

 
writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision
of this Agreement by the other party will be considered a waiver of any other condition or provision or of the same condition or provision at another time. 
 (c) Headings. All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this Agreement. 

(d) Entire Agreement. This Agreement, the Invention Agreement and the Arbitration Agreement constitute the entire agreement of the
parties hereto with respect to their respective subject matter, and supersede in their entirety all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties with
respect to such subject matter. 
 (e) Choice of Law. The laws of the State of California (without reference to its
choice of laws provisions that would lead to the application of the laws of another State) will govern the validity, interpretation, construction and performance of, and any disputes in connection with, this Agreement. 

(f) Severability. If any provisions herein are found to be unenforceable on the grounds that they conflict with applicable laws,
the parties intend that such provisions be replaced, reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by law, and that the remaining provisions will not in any way be affected or impaired
thereby. 
 (g) Withholding. All payments made pursuant to this Agreement will be subject to withholding of applicable
income and employment taxes. 
 (h) Advice of Counsel; Understanding of Obligations. Each party acknowledges that, in
executing this Agreement, such party has had the opportunity to seek the advice of independent legal counsel. This Agreement will not be construed against any party by reason of the drafting or preparation hereof. Executive represents that he or she
has read and understood all of his or her obligations under this Agreement, the Invention Agreement and the Arbitration Agreement, and hereby confirms the reasonableness of the duration, scope and geographic coverage of such obligations. 

(i) Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument. 
 [The remainder of this page is intentionally left blank. The
signature page follows.] 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly
authorized officer, as of the day and year set forth below, to be effective as of the Effective Date. 
  

					
	COMPANY	 	CYTOKINETICS, INCORPORATED
			
		 	By:	 	  

			
		 	Name:	 	  

			
		 	Title:	 	  

			
	EXECUTIVE	 	By:	 	  

			
		 	Name:	 	  

			
		 	Title:EX-4.1

 Exhibit 4.1 

EXECUTION VERSION 
  

 
  

THIRD SUPPLEMENTAL INDENTURE 

GILEAD SCIENCES, INC. 

AND 
 WELLS FARGO BANK,
NATIONAL ASSOCIATION, 
 AS TRUSTEE 

Third Supplemental Indenture 

Dated as of March 7, 2014 

Supplementing the Indenture 

Dated as of March 30, 2011 

2.050% Senior Notes due 2019 

3.700% Senior Notes due 2024 

4.800% Senior Notes due 2044 
  

 
  

 THIRD SUPPLEMENTAL INDENTURE, dated as of March 7, 2014 (this “Third
Supplemental Indenture”), between Gilead Sciences, Inc., a corporation duly organized and existing under the laws of Delaware (herein called the “Company”), and Wells Fargo Bank, National Association, a national banking
association, as Trustee (herein called “Trustee”); 
 RECITALS: 

WHEREAS, the Company and the Trustee have heretofore executed and delivered an Indenture, dated as of March 30, 2011 (as
heretofore supplemented, the “Base Indenture” and, together with the Third Supplemental Indenture, the “Indenture”), providing for the issuance from time to time of the Company’s debentures, notes or other
evidences of indebtedness (herein and therein called the “Securities”), to be issued in one or more series as provided in the Base Indenture;  

WHEREAS, Section 12.1 of the Base Indenture permits the Company and the Trustee to enter into an indenture supplemental to the Base
Indenture to establish the form and terms of any series of Securities; 
 WHEREAS, Section 2.1 of the Base Indenture permits the form
of Securities of any series to be established in an indenture supplemental to the Base Indenture; 
 WHEREAS, Section 3.1 of the Base
Indenture permits certain terms of any series of Securities to be established pursuant to an indenture supplemental to the Base Indenture; 

WHEREAS, pursuant to Sections 2.1 and 3.1 of the Base Indenture, the Company desires to provide for the establishment of three new series of
Securities under the Base Indenture, the form and substance of such Securities and the terms, provisions and conditions thereof to be set forth as provided in the Base Indenture and this Third Supplemental Indenture; and 

WHEREAS, all things necessary to make this Third Supplemental Indenture a valid agreement of the Company, in accordance with its terms, have
been done. 
 NOW, THEREFORE, for and in consideration of the foregoing and the purchase of the Securities of three new series
established by this Third Supplemental Indenture by the holders thereof (the “Holders”), it is mutually agreed, for the equal and proportionate benefit of all such Holders, as follows:  

ARTICLE 1 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 

Section 1.01 Relation to Base Indenture. This Third Supplemental Indenture constitutes a part of the Base Indenture
(the provisions of which, as modified by this Third Supplemental Indenture, shall apply to each series of Notes (as defined in Section 4.01(a))) in respect of such series of Notes but shall not modify, amend or otherwise affect the Base
Indenture insofar as it relates to any other series of Securities or modify, amend or otherwise affect in any manner the terms and conditions of the Securities of any other series. 

  
 1 

 Section 1.02 Definitions. For all purposes of this Third
Supplemental Indenture, the capitalized terms used herein (i) which are defined in this Section 1.02 have the respective meanings assigned hereto in this Section 1.02 and (ii) which are defined in the Base Indenture (and which
are not defined in this Section 1.02) have the respective meanings assigned thereto in the Base Indenture. For all purposes of this Third Supplemental Indenture:  

(a) Unless the context otherwise requires, any reference to an Article or Section refers to an Article or Section, as the case may be, of this
Third Supplemental Indenture; 
 (b) The words “herein,” “hereof” and “hereunder” and words of similar import
refer to this Third Supplemental Indenture as a whole and not to any particular Article, Section or other subdivision; 
 (c) Headings are
for convenience of reference only and do not affect interpretations; and 
 (d) The terms defined in this Section 1.02(d) have the
meanings assigned to them in this Section and include the plural as well as the singular: 
 “Notes” has the meaning set
forth in Section 4.01(a). 
 ARTICLE 2 
  

GENERAL TERMS AND CONDITIONS OF THE 2019 NOTES  

Section 2.01 Terms of the 2019 Notes. Pursuant to Sections 2.1 and 3.1 of the Base Indenture, there is hereby
established a new series of Securities, the terms of which shall be as follows:  
 (a) Designation. There is hereby
authorized and established a new series of Securities under the Base Indenture, known and designated as the “2.050% Senior Notes due 2019” (the “2019 Notes”) of the Company. This series of 2019 Notes is unlimited in
aggregate principal amount. The initial aggregate principal amount of the 2019 Notes to be issued under this Third Supplemental Indenture shall be $500,000,000. Any additional amounts of the 2019 Notes to be issued shall be set forth in a Company
Order. 
 (b) Form and Denominations. The 2019 Notes will be issued only in fully registered form, and the authorized denominations
of the 2019 Notes shall be $2,000 principal amount and any integral multiple of $1,000 in excess thereof. The 2019 Notes will initially be issued in the form of one or more Global Securities substantially in the form of Exhibit A
attached hereto, with such modifications thereto as may be approved by the authorized officer executing the same. The 2019 Notes will be denominated in U.S. dollars and payments of principal, premium, if any, and interest will be made in U.S.
dollars. 
 (c) Maturity Date. The Stated Maturity of principal for the 2019 Notes shall be payable in full on April 1, 2019
(the “2019 Notes Maturity Date’’). 

  
 2 

 (d) Interest. Interest payable on any 2019 Notes Interest Payment Date (as defined below),
the 2019 Notes Maturity Date, or if applicable, the Redemption Date (as determined in accordance with Section 4.2 of the Base Indenture) shall be the amount accrued from, and including, the immediately preceding 2019 Notes Interest Payment Date
in respect of which interest has been paid or duly provided for (or from and including the original issue date of March 7, 2014 if no interest has been paid or duly provided for with respect to the 2019 Notes) to but excluding such 2019 Notes
Interest Payment Date, 2019 Notes Maturity Date or, if applicable, Redemption Date, as the case may be (each, a “2019 Notes Interest Period”). The 2019 Notes will bear interest at the rate of 2.050% per year from
the original issue date thereof to the 2019 Notes Maturity Date. Interest on the 2019 Notes shall be payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2014 (each such date, a
“2019 Notes Interest Payment Date”). The amount of interest payable for any semi-annual 2019 Notes Interest Period will be computed on the basis of a 360-day year consisting of twelve 30-day months. In the event any
2019 Notes Interest Payment Date on or before the 2019 Notes Maturity Date falls on a day that is not a Business Day, the interest payment due on that date will be postponed to the next day that is a Business Day and no interest shall accrue as a
result of such postponement. 
 In the event the 2019 Notes Maturity Date or a Redemption Date for any Note falls on a day that is not a
Business Day, then the related payments of principal, premium, if any, and interest may be made on the next succeeding date that is a Business Day (and no additional interest will accumulate on the amount payable for the period from and after the
2019 Notes Maturity Date for such 2019 Note). Interest due on the 2019 Notes Maturity Date or a Redemption Date (in each case, whether or not a 2019 Notes Interest Payment Date) will be paid to the Person to whom principal of such 2019 Notes is
payable. 
 (e) Sinking Fund; Holder Repurchase Right. The 2019 Notes shall not be subject to any sinking fund or analogous provision
or be redeemable at the option of the Holders. 
 (f) Forms. The 2019 Notes shall be substantially in the form of
Exhibit A attached hereto, with such modifications thereto as may be approved by the authorized officer executing the same. 

(g) Appointment of Agent. The Trustee will initially be the Registrar and Paying Agent with respect to the 2019 Notes. 

(h) Defeasance. Until the applicable 2019 Notes Maturity Date, the 2019 Notes will be subject to Sections 11.2 and 11.3 of the Base
Indenture. 
 (i) Further Issues. The Company may from time to time, without the consent of the Holders of 2019 Notes, issue
additional 2019 Notes. Any such additional 2019 Notes will have the same ranking, interest rate, maturity date and other terms as the 2019 Notes. Any such additional 2019 Notes, together with the 2019 Notes herein provided for, will constitute a
single series of Securities under the Indenture. 

  
 3 

 ARTICLE 3 

GENERAL TERMS AND CONDITIONS OF THE 2024 NOTES  

Section 3.01 Terms of the 2024 Notes. Pursuant to Sections 2.1 and 3.1 of the Base Indenture, there is hereby
established a new series of Securities, the terms of which shall be as follows:  
 (a) Designation. There is hereby
authorized and established a new series of Securities under the Base Indenture, known and designated as the “3.700% Senior Notes due 2024” (the “2024 Notes”) of the Company. This series of 2024 Notes is unlimited in
aggregate principal amount. The initial aggregate principal amount of the 2024 Notes to be issued under this Third Supplemental Indenture shall be $1,750,000,000. Any additional amounts of the 2024 Notes to be issued shall be set forth in a Company
Order. 
 (b) Form and Denominations. The 2024 Notes will be issued only in fully registered form, and the authorized denominations
of the 2024 Notes shall be $2,000 principal amount and any integral multiple of $1,000 in excess thereof. The 2024 Notes will initially be issued in the form of one or more Global Securities substantially in the form of Exhibit B
attached hereto, with such modifications thereto as may be approved by the authorized officer executing the same. The 2024 Notes will be denominated in U.S. dollars and payments of principal, premium, if any, and interest will be made in U.S.
dollars. 
 (c) Maturity Date. The Stated Maturity of principal for the 2024 Notes shall be payable in full on April 1, 2024
(the “2024 Notes Maturity Date’’). 
 (d) Interest. Interest payable on any 2024 Notes Interest Payment Date
(as defined below), the 2024 Notes Maturity Date, or if applicable, the Redemption Date (as determined in accordance with Section 4.2 of the Base Indenture) shall be the amount accrued from, and including, the immediately preceding 2024 Notes
Interest Payment Date in respect of which interest has been paid or duly provided for (or from and including the original issue date of March 7, 2014 if no interest has been paid or duly provided for with respect to the 2024 Notes) to but
excluding such 2024 Notes Interest Payment Date, 2024 Notes Maturity Date or, if applicable, Redemption Date, as the case may be (each, a “2024 Notes Interest Period”). The 2024 Notes will bear interest at the rate of
3.700% per year from the original issue date thereof to the 2024 Notes Maturity Date. Interest on the 2024 Notes shall be payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2014 (each such
date, a “2024 Notes Interest Payment Date”). The amount of interest payable for any semi-annual 2024 Notes Interest Period will be computed on the basis of a 360-day year consisting of twelve 30-day months. In the
event any 2024 Notes Interest Payment Date on or before the 2024 Notes Maturity Date falls on a day that is not a Business Day, the interest payment due on that date will be postponed to the next day that is a Business Day and no interest shall
accrue as a result of such postponement. 
 In the event the 2024 Notes Maturity Date or a Redemption Date for any Note falls on a day that
is not a Business Day, then the related payments of principal, premium, if any, and interest may be made on the next succeeding date that is a Business Day (and no additional 

  
 4 

 
interest will accumulate on the amount payable for the period from and after the 2024 Notes Maturity Date for such 2024 Note). Interest due on the 2024 Notes Maturity Date or a Redemption Date
(in each case, whether or not a 2024 Notes Interest Payment Date) will be paid to the Person to whom principal of such 2024 Notes is payable. 

(e) Sinking Fund; Holder Repurchase Right. The 2024 Notes shall not be subject to any sinking fund or analogous provision or be
redeemable at the option of the Holders. 
 (f) Forms. The 2024 Notes shall be substantially in the form of Exhibit B
attached hereto, with such modifications thereto as may be approved by the authorized officer executing the same. 
 (g) Appointment of
Agent. The Trustee will initially be the Registrar and Paying Agent with respect to the 2024 Notes. 
 (h) Defeasance. Until the
applicable 2024 Notes Maturity Date, the 2024 Notes will be subject to Sections 11.2 and 11.3 of the Base Indenture. 
 (i) Further
Issues. The Company may from time to time, without the consent of the Holders of 2024 Notes, issue additional 2024 Notes. Any such additional 2024 Notes will have the same ranking, interest rate, maturity date and other terms as the 2024 Notes.
Any such additional 2024 Notes, together with the 2024 Notes herein provided for, will constitute a single series of Securities under the Indenture. 

ARTICLE 4 
 GENERAL
TERMS AND CONDITIONS OF THE 2044 NOTES  
 Section 4.01 Terms of the 2044 Notes. Pursuant to
Sections 2.1 and 3.1 of the Base Indenture, there is hereby established a new series of Securities, the terms of which shall be as follows:  

(a) Designation. There is hereby authorized and established a new series of Securities under the Base Indenture, known and designated
as the “4.800% Senior Notes due 2044” (the “2044 Notes” and, together with the 2019 Notes and the 2024 Notes, the “Notes”) of the Company. This series of 2044 Notes is unlimited in aggregate
principal amount. The initial aggregate principal amount of the 2044 Notes to be issued under this Third Supplemental Indenture shall be $1,750,000,000. Any additional amounts of the 2044 Notes to be issued shall be set forth in a Company Order.

 (b) Form and Denominations. The 2044 Notes will be issued only in fully registered form, and the authorized denominations of the
2044 Notes shall be $2,000 principal amount and any integral multiple of $1,000 in excess thereof. The 2044 Notes will initially be issued in the form of one or more Global Securities substantially in the form of Exhibit C attached
hereto, with such modifications thereto as may be approved by the authorized officer executing the same. The 2044 Notes will be denominated in U.S. dollars and payments of principal, premium, if any, and interest will be made in U.S. dollars. 

  
 5 

 (c) Maturity Date. The Stated Maturity of principal for the 2044 Notes shall be payable in
full on April 1, 2044 (the “2044 Notes Maturity Date’’). 
 (d) Interest. Interest payable on any 2044
Notes Interest Payment Date (as defined below), the 2044 Notes Maturity Date, or if applicable, the Redemption Date (as determined in accordance with Section 4.2 of the Base Indenture) shall be the amount accrued from, and including, the
immediately preceding 2044 Notes Interest Payment Date in respect of which interest has been paid or duly provided for (or from and including the original issue date of March 7, 2014 if no interest has been paid or duly provided for with
respect to the 2044 Notes) to but excluding such 2044 Notes Interest Payment Date, 2044 Notes Maturity Date or, if applicable, Redemption Date, as the case may be (each, a “2044 Notes Interest Period”). The 2044 Notes
will bear interest at the rate of 4.800% per year from the original issue date thereof to the 2044 Notes Maturity Date. Interest on the 2044 Notes shall be payable semi-annually in arrears on April 1 and October 1 of each year,
beginning on October 1, 2014 (each such date, a “2044 Notes Interest Payment Date”). The amount of interest payable for any semi-annual 2044 Notes Interest Period will be computed on the basis of a 360-day year
consisting of twelve 30-day months. In the event any 2044 Notes Interest Payment Date on or before the 2044 Notes Maturity Date falls on a day that is not a Business Day, the interest payment due on that date will be postponed to the next day that
is a Business Day and no interest shall accrue as a result of such postponement. 
 In the event the 2044 Notes Maturity Date or a
Redemption Date for any Note falls on a day that is not a Business Day, then the related payments of principal, premium, if any, and interest may be made on the next succeeding date that is a Business Day (and no additional interest will accumulate
on the amount payable for the period from and after the 2044 Notes Maturity Date for such 2044 Note). Interest due on the 2044 Notes Maturity Date or a Redemption Date (in each case, whether or not a 2044 Notes Interest Payment Date) will be paid to
the Person to whom principal of such 2044 Notes is payable. 
 (e) Sinking Fund; Holder Repurchase Right. The 2044 Notes shall not be
subject to any sinking fund or analogous provision or be redeemable at the option of the Holders. 
 (f) Forms. The 2044 Notes shall
be substantially in the form of Exhibit C attached hereto, with such modifications thereto as may be approved by the authorized officer executing the same. 

(g) Appointment of Agent. The Trustee will initially be the Registrar and Paying Agent with respect to the 2044 Notes. 

(h) Defeasance. Until the applicable 2044 Notes Maturity Date, the 2044 Notes will be subject to Sections 11.2 and 11.3 of the Base
Indenture. 
 (i) Further Issues. The Company may from time to time, without the consent of the Holders of 2044 Notes, issue
additional 2044 Notes. Any such additional 2044 Notes will have the same ranking, interest rate, maturity date and other terms as the 2044 Notes. Any such additional 2044 Notes, together with the 2044 Notes herein provided for, will constitute a
single series of Securities under the Indenture. 

  
 6 

 ARTICLE 5 

EVENTS OF DEFAULT 

Section 5.01. Events of Default. Pursuant to Section 7.1 of the Base Indenture, the term “Event of Default”
with respect to each series of Notes shall include, in addition to those otherwise set forth in Section 7.1 of the Base Indenture, the following: the occurrence with respect to any Debt of the Company individually or in the aggregate in excess
of $100,000,000 of (a) an event of default that results in such Debt becoming due and payable prior to its scheduled maturity (after giving effect to any applicable grace period) or (b) the failure to make any payment when due (including
any applicable grace period) which results in the acceleration of the maturity of such Debt, in each case without such acceleration having been rescinded, annulled or otherwise cured. 

ARTICLE 6 

REDEMPTION OF THE NOTES 

Section 6.01 Optional Redemption by Company. Each series of Notes may be redeemed at the option of the Company on the terms
and conditions set forth in the form of Note as set forth as Exhibit A, Exhibit B or Exhibit C, as applicable. 

ARTICLE 7 
 CHANGE OF
CONTROL 
 Section 7.01 Offer to Purchase Upon Change of Control Triggering Event. Upon the occurrence of a
Change of Control Triggering Event (as defined in the form of Note set forth as Exhibit A, Exhibit B or Exhibit C, as applicable), except with respect to any series of Notes for which the Company has exercised its option to
redeem the Notes of such series in full pursuant to Section 6.01, the Company shall be required to make an offer to each Holder of the applicable series of Notes to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000
in excess thereof) of that Holder’s applicable series of Notes on the terms and conditions set forth in the form of Note set forth as Exhibit A, Exhibit B or Exhibit C, as applicable. 

ARTICLE 8 

MISCELLANEOUS 

Section 8.01 Relationship to Existing Base Indenture. This Third Supplemental Indenture is a supplemental
indenture within the meaning of the Base Indenture. The Base Indenture, as supplemented and amended by this Third Supplemental Indenture, is in all respects ratified, confirmed and approved and, with respect to each series of Notes, the Base
Indenture, as supplemented and amended by this Third Supplemental Indenture, shall be read, taken and construed as one and the same instrument. 

  
 7 

 Section 8.02 Modification of the Existing Base Indenture. Except
as expressly modified by this Third Supplemental Indenture, the provisions of the Base Indenture shall govern the terms and conditions of each series of Notes.  

Section 8.03 Governing Law. This Third Supplemental Indenture shall be governed by and construed in
accordance with the laws of the State of New York. 
 Section 8.04 Counterparts. This Third
Supplemental Indenture may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.  

Section 8.05 Trustee Makes No Representation. The recitals contained herein are made by the Company and not
by the Trustee, and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representation as to the validity or sufficiency of this Third Supplemental Indenture (except for its execution thereof and its certificates
of authentication of any series of Notes).  
 Section 8.06 Separability. In case any provision in the Base
Indenture, this Third Supplemental Indenture or any series of Notes shall for any reason be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions shall not in any way be affected or
impaired thereby. 
 [Signature page follows] 

  
 8 

 IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental Indenture to be
duly executed and attested all as of the day and year first above written.  
 Date: March 7, 2014 

 

					
	GILEAD SCIENCES, INC.,
	as Issuer
		
	By:	 	 /s/ Robin L. Washington

		 	Name:	 	Robin L. Washington
		 	Title:	 	Executive Vice President and Chief Financial Officer
	
	WELLS FARGO BANK,
	 NATIONAL ASSOCIATION,

as Trustee

		
	By:	 	 /s/ Yana Kislenko

		 	Name:	 	Yana Kislenko
		 	Title:	 	Vice President

 [Third Supplemental Indenture] 

 EXHIBIT A 

FORM OF 2019 SENIOR NOTE 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY
OR A NOMINEE OF THE DEPOSITARY WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE OR ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.  
 GILEAD SCIENCES, INC. 

 

			
	No.             	  	 CUSIP NO. 375558 AV5

$             

 Interest. Gilead Sciences, Inc., a corporation duly incorporated and existing under the laws of the
State of Delaware (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered
assigns, the principal sum of                     DOLLARS
($                    ), as revised by the Schedule of Increases or Decreases in Global Security attached hereto, on April 1, 2019 and to pay
interest thereon from March 7, 2014 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually on April 1 and October 1 in each year, commencing October 1, 2014, at the rate
of 2.050% per annum, until the principal hereof is paid or made available for payment.  
 Method of Payment. The
interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of
business on the Regular Record Date for such interest, which shall be the March 15 or September 15 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. 

  
 A-1 

 
Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this
Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this
series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such
notice as may be required by such exchange, all as more fully provided in said Indenture. 
 Payment of the principal of (and premium, if
any) and interest on this Security will be made at the office or agency of the Trustee maintained for that purpose in New York, New York, in such coin or currency of the United States of America as at the time of payment is legal tender for payment
of public and private debts. 
 Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which
further provisions shall for all purposes have the same effect as if set forth at this place. 
 Authentication. Unless the
certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 A-2 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
  

			
	GILEAD SCIENCES, INC.
		
	By:	 	  

		 	 Name:
 Title:

 [Global 2019 Note] 

  
 A-3 

 [FORM OF CERTIFICATION OF AUTHENTICATION] 

CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

					
	Date of authentication:	 	 WELLS FARGO BANK,

NATIONAL ASSOCIATION,
 as Trustee

			
		 	By:	 	  

		 		 	Authorized Signatory

  
 A-4 

 [FORM OF REVERSE OF 2019 NOTE] 

Indenture. This Security is one of a duly authorized issue of securities of the Company (herein called the
“Securities”), issued and to be issued in one or more series under an Indenture, dated as of March 30, 2011 (as heretofore supplemented, herein called the “Base Indenture”, which term shall have the meaning
assigned to it in such instrument), as supplemented by a Third Supplemental Indenture dated as of March 7, 2014 (herein called the “Third Supplemental Indenture”, and together with the Base Indenture, the
“Indenture”), between the Company and Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is hereby made to
the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be,
authenticated and delivered. This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to $500,000,000. The Company may at any time issue additional securities under the Indenture in unlimited
amounts having the same terms as the Securities.  
 Optional Redemption. The Securities of this series are subject to
redemption at the Company’s option, at any time and from time to time, in whole or in part, upon not less than 30 nor more than 60 days’ notice mailed to each Holder of Securities to be redeemed at his address as it appears in the
records of the Registrar, on any date prior to their Stated Maturity at a Redemption Price equal to the greater of (i) 100% of the principal amount of such Securities to be redeemed, plus accrued and unpaid interest thereon to the Redemption
Date or (ii) as determined by an Independent Investment Banker (as defined below), the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest
accrued as of the Redemption Date) discounted to the Redemption Date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below), plus 10 basis points, plus in each case accrued and
unpaid interest thereon to the Redemption Date; provided that unless the Company defaults in payment of the Redemption Price, on or after the Redemption Date, interest will cease to accrue on the Securities or portions thereof called for
redemption. 
 For purposes of determining the optional redemption price, the following definitions are applicable: 

“Treasury Rate” means, with respect to any Redemption Date, the rate per annum equal to the semi-annual equivalent
yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such Redemption Date. The semi-annual equivalent
yield to maturity of the Comparable Treasury Issue will be computed as of the third business day immediately preceding the Redemption Date.  

“Comparable Treasury Issue” means the United States Treasury security or securities selected by the Independent
Investment Banker as having a maturity comparable to the remaining term of the Securities to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt
securities of comparable maturity to the remaining term of the Securities.  

  
 A-5 

 “Comparable Treasury Price” means, with respect to any Redemption Date,
(1) the average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest Reference Treasury Dealer Quotations, or (2) if the Independent Investment Banker obtains fewer than four
Reference Treasury Dealer Quotations, the average of all Reference Treasury Dealer Quotations so received. 

“Independent Investment Banker” means the Reference Treasury Dealer appointed by the Company. 

“Reference Treasury Dealer” means Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC,
their successors and two other nationally recognized investment banking firms; provided, however, that, if the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury
Dealer”), the Company shall substitute therefor another nationally recognized investment banking firm that is a Primary Treasury Dealer. 

“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date,
the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue for the Securities (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent
Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such Redemption Date.  

In the event of redemption of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed
portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. 
 Change of Control. If a
Change of Control Triggering Event occurs, unless the Company has exercised its right to redeem the Securities as described above, it will be required to make an offer to repurchase all, or any part (equal to $2,000 or an integral multiple of $1,000
in excess thereof), of each Holder’s Securities pursuant to the offer described below (the “Change of Control Offer”) on the terms set forth herein. In the Change of Control Offer, the Company will be required to offer payment
in cash equal to 101% of the aggregate principal amount of Securities repurchased plus accrued and unpaid interest, if any, on the Securities repurchased, to the date of repurchase (the “Change of Control Payment”), subject to the
rights of Holders of Securities on the relevant record date to receive interest due on the relevant Interest Payment Date. 

Within 30 days following any Change of Control Triggering Event or, at the Company’s option, prior to any Change of Control but
after the public announcement of the pending Change of Control, the Company will be required to mail a notice to Holders of Securities describing the transaction or transactions that constitute or may constitute the Change of Control Triggering
Event and offering to repurchase the Securities on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is mailed (the “Change of Control Payment Date”),
pursuant to the procedures required herein and described in such notice. The Company must comply with the requirements of Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other
securities  

  
 A-6 

 
laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Securities as a result of a Change of Control Triggering Event. To
the extent that the provisions of any securities laws or regulations conflict with the Change of Control provisions herein, the Company will be required to comply with the applicable securities laws and regulations and will not be deemed to have
breached its obligations under the Change of Control provisions herein by virtue of such conflicts. 
 On the Change of Control Payment
Date, the Company will be required, to the extent lawful, to: 
 (a) accept for payment all Securities or portions of Securities properly
tendered, and not validly withdrawn, pursuant to the Change of Control Offer; 
 (b) deposit with the Paying Agent an amount equal to the
Change of Control Payment in respect of all Securities or portions of Securities properly tendered and not validly withdrawn; and 
 (c)
deliver or cause to be delivered to the Trustee the Securities properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Securities or portions of Securities being purchased by the Company. 

The Paying Agent will be required to mail promptly to each Holder who properly tendered Securities the purchase price for such
Securities and the Trustee will be required to authenticate and mail (or cause to be transferred by book entry) promptly to each such Holder a new Security equal in principal amount to any unpurchased portion of the Securities surrendered, if any;
provided that each new Security will be in a principal amount of $2,000 or an integral multiple of $1,000 in excess thereof.  

Notwithstanding the foregoing, the Company will not be required to make a Change of Control Offer with respect to the Securities upon the
occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for such an offer made by the Company and the third party purchases all such
Securities properly tendered and not validly withdrawn under its offer. Further, the Company will not be required to repurchase any Securities if there has occurred and is continuing on the Change of Control Payment Date an Event of Default. 

For purposes of the foregoing discussion of a repurchase at the option of Holders, the following definitions are applicable: 

“Capital Stock” means the capital stock of every class whether now or hereafter authorized, regardless of whether such
capital stock shall be limited to a fixed sum or percentage with respect to the rights of the holders thereof to participate in dividends and in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of
such corporation.  

  
 A-7 

 “Change of Control” means the occurrence of any of the following:

 (a) the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in
one or more series of related transactions, of all or substantially all of the Company’s assets and the assets of its Subsidiaries, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act),
other than the Company or one of its Subsidiaries; 
 (b) the consummation of any transaction (including, without limitation, any merger or
consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than the Company or one of its Subsidiaries, becomes the “beneficial owner” (as defined in Rule
13d-3 under the Exchange Act), directly or indirectly, of more than 50% of the Company’s then outstanding Voting Stock or other Voting Stock into which the Company’s Voting Stock is reclassified, consolidated, exchanged or changed,
measured by voting power rather than number of shares; 
 (c) the Company consolidates, or merges with or into any person, or any person
consolidates with, or merges with or into, the Company, in any such event pursuant to a transaction in which any of its Voting Stock or the Voting Stock of such other person is converted into or exchanged for cash, securities or other property,
other than any such transaction where the shares of the Company’s Voting Stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving person or any
direct or indirect parent company of the surviving person immediately after giving effect to such transaction; 
 (d) the first day on which
a majority of the Company’s members of its board of directors are not Continuing Directors; or 
 (e) the adoption of a plan relating
to the Company’s liquidation or dissolution. 
 Notwithstanding paragraphs (a), (b) and (c) above, a transaction will not be
considered to be a Change of Control if (a) the Company becomes a direct or indirect wholly-owned subsidiary of a holding company and (b)(x) immediately following that transaction, the direct or indirect holders of the Voting Stock of the
holding company are substantially the same as the holders of the Company’s Voting Stock immediately prior to that transaction or (y) immediately following that transaction, no person is the beneficial owner, directly or indirectly, of more
than 50% of the Voting Stock of such holding company. 
 “Change of Control Triggering Event” means the occurrence
of both a Change of Control and a Rating Event. 
 “Continuing Directors” means, as of any date of
determination, any member of the Company’s board of directors who (a) was a member of such board of directors on March 7, 2014 or (b) was nominated for election, elected or appointed to such board of directors with the approval
of a majority of the Continuing Directors who were members of such board of directors at the time of such nomination, election or appointment (either by a specific vote or by approval of a proxy statement in which such member was named as a nominee
for election as a director). 
 “Investment Grade” means a rating of Baa3 or better by Moody’s (or its
equivalent under any successor rating categories of Moody’s) and a rating of BBB- or better by S&P (or its equivalent under any successor rating categories of S&P) or the equivalent investment grade credit rating from any additional
Rating Agency or Rating Agencies selected by the Company.  

  
 A-8 

 “Moody’s” means Moody’s Investors Service, Inc., a subsidiary
of Moody’s Corporation, and its successors.  
 “Rating Agencies” means (a) each of Moody’s
and S&P; and (b) if any of Moody’s or S&P ceases to rate the Securities or fails to make a rating of the Securities publicly available for reasons outside of the Company’s control, a “nationally recognized statistical
rating organization” within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act that is selected by the Company (as certified by a resolution of the Company’s board of directors) as a replacement agency for Moody’s or
S&P, or both of them, as the case may be. 
 “Rating Event” means, with respect to the Securities, the rating on
the Securities is lowered below Investment Grade by each of the Rating Agencies on any date beginning on the date of public notice of an arrangement that could result in a Change of Control until the end of the 60-day period following public notice
of the occurrence of the Change of Control (which 60-day period shall be extended so long as the rating of the Securities is under publicly announced consideration for possible downgrade by any of the Rating Agencies). 

“S&P” means Standard & Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc., and
its successors.  
 “Voting Stock” means, with respect to any specified person as of any date, the Capital
Stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person. 
 The
Indenture contains provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth
in the Indenture, which provisions apply to this Security. This Security is not subject to repayment at the Holder’s option. 
 No
reference herein to the Indenture and no provision of this Security or the Indenture shall affect or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of, premium, if any, and interest on this Security
at the respective due dates, place and rate, and in the Currency herein prescribed. 
 Default and Remedies. If an Event of Default
with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture.  

Amendment, Modification and Waiver. The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in
principal amount of the Securities at the time outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time
outstanding, on behalf of the  

  
 A-9 

 
Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any
such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu
hereof, whether or not notation of such consent or waiver is made upon this Security. 
 Denominations; Transfer and Exchange. As
provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the records of the Registrar, upon surrender of this Security for registration of transfer at the office or agency of the
Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar duly executed by, the
Holder hereof or the Holder’s attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the
designated transferee or transferees.  
 The Securities of this series are issuable only in registered form in denominations of
$2,000 and any integral multiple of $1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this
series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same. 
 No service charge
shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

Persons Deemed Owners. Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent
of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by
notice to the contrary.  
 Miscellaneous. The Indenture and the Securities, including this Security, shall be
governed by and construed in accordance with the laws of the State of New York. 
 All terms used in this Security and not defined
herein shall have the meanings assigned to them in the Indenture. 
 Pursuant to a recommendation promulgated by the Committee on Uniform
Security Identification Procedures, the Company has caused “CUSIP” numbers to be printed on the Securities as a convenience to the Holders of the Securities. No representation is made as to the correctness or accuracy of such CUSIP numbers
as printed on the Securities, and reliance may be placed only on the other identification numbers printed hereon. 
 Unless the certificate
of authentication hereon has been executed by or on behalf of the Trustee by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 A-10 

 ASSIGNMENT FORM 

FOR VALUE RECEIVED, the undersigned hereby 

sells, assigns and transfers unto 
 PLEASE INSERT
SOCIAL 
 SECURITY OR OTHER IDENTIFYING 
 NUMBER OF ASSIGNEE

  
  

 
  

(Please Print or Typewrite Name and Address, including Zip Code, of Assignee) 
  

 
 the within Security of Gilead Sciences, Inc. and
                                         
                hereby does irrevocably constitute and appoint 
  

 
 Attorney to transfer said Security on the books of the
within-named Company with full power of substitution in the premises 
  

			
	Dated:	 	  

  

			
	Signature	 	  

 NOTICE: The signature to this assignment must correspond with the name as it appears on the first page of the within Security
in every particular, without alteration or enlargement or any change whatever. 
  

			
	Signature
Guaranteed:	  	  

 NOTICE: Signature(s) must be guaranteed by an “eligible guarantor institution” that is a member or
participant in a “signature guarantee program” (e.g., the Securities Transfer Agents Medallion Program, the Stock Exchange Medallion Program and the New York Stock Exchange Medallion Program). 

  
 A-11 

 SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY 

The following increases or decreases in this Global Security have been made: 

 

									
	 Date of

Exchange
	 	 Amount of increase in
Principal Amount of
this Global
Security
	 	 Amount of decrease
in Principal Amount

of this Global
 Security
	 	 Principal Amount of

this Global Security
 following
such
 decrease or increase
	 	 Signature of

authorized signatory
 of
Trustee

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

  
 A-12 

 EXHIBIT B 

FORM OF 2024 SENIOR NOTE 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY
OR A NOMINEE OF THE DEPOSITARY WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE OR ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.  
 GILEAD SCIENCES, INC. 

 

			
	No.             	  	 CUSIP NO. 375558 AW3

$            

 Interest. Gilead Sciences, Inc., a corporation duly incorporated and existing under the laws of the
State of Delaware (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered
assigns, the principal sum of                     DOLLARS
($                    ), as revised by the Schedule of Increases or Decreases in Global Security attached hereto, on April 1, 2024 and to pay
interest thereon from March 7, 2014 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually on April 1 and October 1 in each year, commencing October 1, 2014, at the rate
of 3.700% per annum, until the principal hereof is paid or made available for payment.  
 Method of Payment. The
interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of
business on the Regular Record Date for such interest, which shall be the March 15 or September 15 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. 

  
 B-1 

 
Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this
Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this
series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such
notice as may be required by such exchange, all as more fully provided in said Indenture. 
 Payment of the principal of (and premium, if
any) and interest on this Security will be made at the office or agency of the Trustee maintained for that purpose in New York, New York, in such coin or currency of the United States of America as at the time of payment is legal tender for payment
of public and private debts. 
 Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which
further provisions shall for all purposes have the same effect as if set forth at this place. 
 Authentication. Unless the
certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 B-2 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
  

			
	GILEAD SCIENCES, INC.
		
	By:	 	  

		 	 Name:
 Title:

 [Global 2024 Note] 

  
 B-3 

 [FORM OF CERTIFICATION OF AUTHENTICATION] 

CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

					
	Date of authentication:	 	 WELLS FARGO BANK,

NATIONAL ASSOCIATION,
 as Trustee

			
		 	By:	 	  

		 		 	Authorized Signatory

  
 B-4 

 [FORM OF REVERSE OF 2024 NOTE] 

Indenture. This Security is one of a duly authorized issue of securities of the Company (herein called the
“Securities”), issued and to be issued in one or more series under an Indenture, dated as of March 30, 2011 (as heretofore supplemented, herein called the “Base Indenture”, which term shall have the meaning
assigned to it in such instrument), as supplemented by a Third Supplemental Indenture dated as of March 7, 2014 (herein called the “Third Supplemental Indenture”, and together with the Base Indenture, the
“Indenture”), between the Company and Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is hereby made to
the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be,
authenticated and delivered. This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to $1,750,000,000. The Company may at any time issue additional securities under the Indenture in
unlimited amounts having the same terms as the Securities.  
 Optional Redemption. The Securities of this series are subject
to redemption at the Company’s option, at any time and from time to time, in whole or in part, upon not less than 30 nor more than 60 days’ notice mailed to each Holder of Securities to be redeemed at his address as it appears in the
records of the Registrar, on any date prior to their Stated Maturity at a Redemption Price equal to the greater of (i) 100% of the principal amount of such Securities to be redeemed, plus accrued and unpaid interest thereon to the Redemption
Date or (ii) as determined by an Independent Investment Banker (as defined below), the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest
accrued as of the Redemption Date) discounted to the Redemption Date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below), plus 15 basis points, plus in each case accrued and
unpaid interest thereon to the Redemption Date; provided that unless the Company defaults in payment of the Redemption Price, on or after the Redemption Date, interest will cease to accrue on the Securities or portions thereof called for
redemption. 
 For purposes of determining the optional redemption price, the following definitions are applicable: 

“Treasury Rate” means, with respect to any Redemption Date, the rate per annum equal to the semi-annual equivalent
yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such Redemption Date. The semi-annual equivalent
yield to maturity of the Comparable Treasury Issue will be computed as of the third business day immediately preceding the Redemption Date.  

“Comparable Treasury Issue” means the United States Treasury security or securities selected by the Independent
Investment Banker as having a maturity comparable to the remaining term of the Securities to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt
securities of comparable maturity to the remaining term of the Securities.  

  
 B-5 

 “Comparable Treasury Price” means, with respect to any Redemption Date,
(1) the average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest Reference Treasury Dealer Quotations, or (2) if the Independent Investment Banker obtains fewer than four
Reference Treasury Dealer Quotations, the average of all Reference Treasury Dealer Quotations so received. 

“Independent Investment Banker” means the Reference Treasury Dealer appointed by the Company. 

“Reference Treasury Dealer” means Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC,
their successors and two other nationally recognized investment banking firms; provided, however, that, if the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury
Dealer”), the Company shall substitute therefor another nationally recognized investment banking firm that is a Primary Treasury Dealer. 

“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date,
the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue for the Securities (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent
Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such Redemption Date.  

The Securities of this series are also subject to redemption at the Company’s option, at any time on or after January 1, 2024, in
whole or in part, upon not less than 30 nor more than 60 days’ notice mailed to each Holder of Securities to be redeemed at his address as it appears in the records of the Registrar, at a Redemption Price equal to 100% of the principal amount
of the Securities to be redeemed, plus accrued and unpaid interest to the Redemption Date. 
 In the event of redemption of this Security in
part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. 

Change of Control. If a Change of Control Triggering Event occurs, unless the Company has exercised its right to redeem
the Securities as described above, it will be required to make an offer to repurchase all, or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof), of each Holder’s Securities pursuant to the offer described below (the
“Change of Control Offer”) on the terms set forth herein. In the Change of Control Offer, the Company will be required to offer payment in cash equal to 101% of the aggregate principal amount of Securities repurchased plus accrued
and unpaid interest, if any, on the Securities repurchased, to the date of repurchase (the “Change of Control Payment”), subject to the rights of Holders of Securities on the relevant record date to receive interest due on the
relevant Interest Payment Date. 
 Within 30 days following any Change of Control Triggering Event or, at the Company’s option,
prior to any Change of Control but after the public announcement of the pending Change of Control, the Company will be required to mail a notice to Holders of Securities describing the 

  
 B-6 

 
transaction or transactions that constitute or may constitute the Change of Control Triggering Event and offering to repurchase the Securities on the date specified in the notice, which date
will be no earlier than 30 days and no later than 60 days from the date such notice is mailed (the “Change of Control Payment Date”), pursuant to the procedures required herein and described in such notice. The Company must comply
with the requirements of Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in
connection with the repurchase of the Securities as a result of a Change of Control Triggering Event. To the extent that the provisions of any securities laws or regulations conflict with the Change of Control provisions herein, the Company will be
required to comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control provisions herein by virtue of such conflicts.  

On the Change of Control Payment Date, the Company will be required, to the extent lawful, to: 

(a) accept for payment all Securities or portions of Securities properly tendered, and not validly withdrawn, pursuant to the Change of
Control Offer; 
 (b) deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Securities or
portions of Securities properly tendered and not validly withdrawn; and 
 (c) deliver or cause to be delivered to the Trustee the
Securities properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Securities or portions of Securities being purchased by the Company. 

The Paying Agent will be required to mail promptly to each Holder who properly tendered Securities the purchase price for such
Securities and the Trustee will be required to authenticate and mail (or cause to be transferred by book entry) promptly to each such Holder a new Security equal in principal amount to any unpurchased portion of the Securities surrendered, if any;
provided that each new Security will be in a principal amount of $2,000 or an integral multiple of $1,000 in excess thereof.  

Notwithstanding the foregoing, the Company will not be required to make a Change of Control Offer with respect to the Securities upon the
occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for such an offer made by the Company and the third party purchases all such
Securities properly tendered and not validly withdrawn under its offer. Further, the Company will not be required to repurchase any Securities if there has occurred and is continuing on the Change of Control Payment Date an Event of Default. 

For purposes of the foregoing discussion of a repurchase at the option of Holders, the following definitions are applicable: 

“Capital Stock” means the capital stock of every class whether now or hereafter authorized, regardless of whether such
capital stock shall be limited to a fixed sum or percentage with respect to the rights of the holders thereof to participate in dividends and in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of
such corporation.  

  
 B-7 

 “Change of Control” means the occurrence of any of the following:

 (a) the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in
one or more series of related transactions, of all or substantially all of the Company’s assets and the assets of its Subsidiaries, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act),
other than the Company or one of its Subsidiaries; 
 (b) the consummation of any transaction (including, without limitation, any merger or
consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than the Company or one of its Subsidiaries, becomes the “beneficial owner” (as defined in Rule
13d-3 under the Exchange Act), directly or indirectly, of more than 50% of the Company’s then outstanding Voting Stock or other Voting Stock into which the Company’s Voting Stock is reclassified, consolidated, exchanged or changed,
measured by voting power rather than number of shares; 
 (c) the Company consolidates, or merges with or into any person, or any person
consolidates with, or merges with or into, the Company, in any such event pursuant to a transaction in which any of its Voting Stock or the Voting Stock of such other person is converted into or exchanged for cash, securities or other property,
other than any such transaction where the shares of the Company’s Voting Stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving person or any
direct or indirect parent company of the surviving person immediately after giving effect to such transaction; 
 (d) the first day on which
a majority of the Company’s members of its board of directors are not Continuing Directors; or 
 (e) the adoption of a plan relating
to the Company’s liquidation or dissolution. 
 Notwithstanding paragraphs (a), (b) and (c) above, a transaction will not be
considered to be a Change of Control if (a) the Company becomes a direct or indirect wholly-owned subsidiary of a holding company and (b)(x) immediately following that transaction, the direct or indirect holders of the Voting Stock of the
holding company are substantially the same as the holders of the Company’s Voting Stock immediately prior to that transaction or (y) immediately following that transaction, no person is the beneficial owner, directly or indirectly, of more
than 50% of the Voting Stock of such holding company. 
 “Change of Control Triggering Event” means the occurrence
of both a Change of Control and a Rating Event. 
 “Continuing Directors” means, as of any date of
determination, any member of the Company’s board of directors who (a) was a member of such board of directors on March 7, 2014 or (b) was nominated for election, elected or appointed to such board of directors with the approval
of a majority of the Continuing Directors who were members of such board of directors at the time of such nomination, election or appointment (either by a specific vote or by approval of a proxy statement in which such member was named as a nominee
for election as a director). 

  
 B-8 

 “Investment Grade” means a rating of Baa3 or better by Moody’s (or
its equivalent under any successor rating categories of Moody’s) and a rating of BBB- or better by S&P (or its equivalent under any successor rating categories of S&P) or the equivalent investment grade credit rating from any additional
Rating Agency or Rating Agencies selected by the Company.  
 “Moody’s” means Moody’s Investors
Service, Inc., a subsidiary of Moody’s Corporation, and its successors.  
 “Rating Agencies” means
(a) each of Moody’s and S&P; and (b) if any of Moody’s or S&P ceases to rate the Securities or fails to make a rating of the Securities publicly available for reasons outside of the Company’s control, a
“nationally recognized statistical rating organization” within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act that is selected by the Company (as certified by a resolution of the Company’s board of directors) as a
replacement agency for Moody’s or S&P, or both of them, as the case may be. 
 “Rating Event” means, with
respect to the Securities, the rating on the Securities is lowered below Investment Grade by each of the Rating Agencies on any date beginning on the date of public notice of an arrangement that could result in a Change of Control until the end of
the 60-day period following public notice of the occurrence of the Change of Control (which 60-day period shall be extended so long as the rating of the Securities is under publicly announced consideration for possible downgrade by any of the Rating
Agencies). 
 “S&P” means Standard & Poor’s Ratings Services, a division of The McGraw-Hill
Companies, Inc., and its successors.  
 “Voting Stock” means, with respect to any specified person as of any
date, the Capital Stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person. 

The Indenture contains provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and
Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture, which provisions apply to this Security. This Security is not subject to repayment at the Holder’s option. 

No reference herein to the Indenture and no provision of this Security or the Indenture shall affect or impair the obligation of the Company,
which is absolute and unconditional, to pay the principal of, premium, if any, and interest on this Security at the respective due dates, place and rate, and in the Currency herein prescribed. 

Default and Remedies. If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of
the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture.  

Amendment, Modification and Waiver. The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the  

  
 B-9 

 
Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority
in principal amount of the Securities at the time outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time
outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by
the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not
notation of such consent or waiver is made upon this Security. 
 Denominations; Transfer and Exchange. As provided in the Indenture
and subject to certain limitations therein set forth, the transfer of this Security is registrable in the records of the Registrar, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place
where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar duly executed by, the Holder hereof or the
Holder’s attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or
transferees.  
 The Securities of this series are issuable only in registered form in denominations of $2,000 and any integral
multiple of $1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor
of a different authorized denomination, as requested by the Holder surrendering the same. 
 No service charge shall be made to a Holder for
any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

Persons Deemed Owners. Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent
of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by
notice to the contrary.  
 Miscellaneous. The Indenture and the Securities, including this Security, shall be
governed by and construed in accordance with the laws of the State of New York. 
 All terms used in this Security and not defined
herein shall have the meanings assigned to them in the Indenture. 
 Pursuant to a recommendation promulgated by the Committee on Uniform
Security Identification Procedures, the Company has caused “CUSIP” numbers to be printed on the Securities as a convenience to the Holders of the Securities. No representation is made as to the correctness or accuracy of such CUSIP numbers
as printed on the Securities, and reliance may be placed only on the other identification numbers printed hereon. 

  
 B-10 

 Unless the certificate of authentication hereon has been executed by or on behalf of the Trustee
by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 B-11 

 ASSIGNMENT FORM 

FOR VALUE RECEIVED, the undersigned hereby 

sells, assigns and transfers unto 
 PLEASE INSERT
SOCIAL 
 SECURITY OR OTHER IDENTIFYING 
 NUMBER OF ASSIGNEE

  
  

 
  

(Please Print or Typewrite Name and Address, including Zip Code, of Assignee) 
  

 
 the within Security of Gilead Sciences, Inc. and
                                        
hereby does irrevocably constitute and appoint 
  
  

Attorney to transfer said Security on the books of the within-named Company with full power of substitution in the premises 

 

			
	Dated:	 	  

  

			
	 Signature
	 	  

 NOTICE: The signature to this assignment must correspond with the name as it appears on the first page of the within Security
in every particular, without alteration or enlargement or any change whatever. 
  

			
	Signature Guaranteed:	 	  

 NOTICE: Signature(s) must be guaranteed by an “eligible guarantor institution” that is a member or
participant in a “signature guarantee program” (e.g., the Securities Transfer Agents Medallion Program, the Stock Exchange Medallion Program and the New York Stock Exchange Medallion Program). 

  
 B-12 

 SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY 

The following increases or decreases in this Global Security have been made: 

 

									
	 Date of

Exchange
	 	 Amount of increase in

Principal Amount of
 this Global
Security
	 	 Amount of decrease

in Principal Amount
 of this
Global
 Security
	 	 Principal Amount of

this Global Security
 following
such
 decrease or increase
	 	 Signature of

authorized signatory
 of
Trustee

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

  
 B-13 

 EXHIBIT C 

FORM OF 2044 SENIOR NOTE 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY
OR A NOMINEE OF THE DEPOSITARY WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE OR ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO
TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.  
 GILEAD SCIENCES, INC. 

 

			
	No.             	 	 CUSIP NO. 375558 AX1

$            

 Interest. Gilead Sciences, Inc., a corporation duly incorporated and existing under the laws of the
State of Delaware (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered
assigns, the principal sum of                     DOLLARS
($                    ), as revised by the Schedule of Increases or Decreases in Global Security attached hereto, on April 1, 2044 and to pay
interest thereon from March 7, 2014 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually on April 1 and October 1 in each year, commencing October 1, 2014, at the rate
of 4.800% per annum, until the principal hereof is paid or made available for payment.  
 Method of Payment. The
interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of
business on the Regular Record Date for such interest, which shall be the March 15 or September 15 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. 

  
 C-1 

 
Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this
Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this
series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such
notice as may be required by such exchange, all as more fully provided in said Indenture. 
 Payment of the principal of (and premium, if
any) and interest on this Security will be made at the office or agency of the Trustee maintained for that purpose in New York, New York, in such coin or currency of the United States of America as at the time of payment is legal tender for payment
of public and private debts. 
 Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which
further provisions shall for all purposes have the same effect as if set forth at this place. 
 Authentication. Unless the
certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 C-2 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
  

			
	GILEAD SCIENCES, INC.
		
	By:	 	  

		 	 Name:
 Title:

 [Global 2044 Note] 

  
 C-3 

 [FORM OF CERTIFICATION OF AUTHENTICATION] 

CERTIFICATE OF AUTHENTICATION 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

					
	Date of authentication:	 	 WELLS FARGO BANK,

NATIONAL ASSOCIATION,
 as Trustee

			
		 	By:	 	  

		 		 	Authorized Signatory

  
 C-4 

 [FORM OF REVERSE OF 2044 NOTE] 

Indenture. This Security is one of a duly authorized issue of securities of the Company (herein called the
“Securities”), issued and to be issued in one or more series under an Indenture, dated as of March 30, 2011 (as heretofore supplemented, herein called the “Base Indenture”, which term shall have the meaning
assigned to it in such instrument), as supplemented by a Third Supplemental Indenture dated as of March 7, 2014 (herein called the “Third Supplemental Indenture”, and together with the Base Indenture, the
“Indenture”), between the Company and Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is hereby made to
the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be,
authenticated and delivered. This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to $1,750,000,000. The Company may at any time issue additional securities under the Indenture in
unlimited amounts having the same terms as the Securities.  
 Optional Redemption. The Securities of this series are subject
to redemption at the Company’s option, at any time and from time to time, in whole or in part, upon not less than 30 nor more than 60 days’ notice mailed to each Holder of Securities to be redeemed at his address as it appears in the
records of the Registrar, on any date prior to their Stated Maturity at a Redemption Price equal to the greater of (i) 100% of the principal amount of such Securities to be redeemed, plus accrued and unpaid interest thereon to the Redemption
Date or (ii) as determined by an Independent Investment Banker (as defined below), the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest
accrued as of the Redemption Date) discounted to the Redemption Date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below), plus 20 basis points, plus in each case accrued and
unpaid interest thereon to the Redemption Date; provided that unless the Company defaults in payment of the Redemption Price, on or after the Redemption Date, interest will cease to accrue on the Securities or portions thereof called for
redemption. 
 For purposes of determining the optional redemption price, the following definitions are applicable: 

“Treasury Rate” means, with respect to any Redemption Date, the rate per annum equal to the semi-annual equivalent
yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such Redemption Date. The semi-annual equivalent
yield to maturity of the Comparable Treasury Issue will be computed as of the third business day immediately preceding the Redemption Date.  

“Comparable Treasury Issue” means the United States Treasury security or securities selected by the Independent
Investment Banker as having a maturity comparable to the remaining term of the Securities to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt
securities of comparable maturity to the remaining term of the Securities.  

  
 C-5 

 “Comparable Treasury Price” means, with respect to any Redemption Date,
(1) the average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest Reference Treasury Dealer Quotations, or (2) if the Independent Investment Banker obtains fewer than four
Reference Treasury Dealer Quotations, the average of all Reference Treasury Dealer Quotations so received. 

“Independent Investment Banker” means the Reference Treasury Dealer appointed by the Company. 

“Reference Treasury Dealer” means Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC,
their successors and two other nationally recognized investment banking firms; provided, however, that, if the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury
Dealer”), the Company shall substitute therefor another nationally recognized investment banking firm that is a Primary Treasury Dealer. 

“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date,
the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue for the Securities (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent
Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such Redemption Date.  

The Securities of this series are also subject to redemption at the Company’s option, at any time on or after October 1, 2043, in
whole or in part, upon not less than 30 nor more than 60 days’ notice mailed to each Holder of Securities to be redeemed at his address as it appears in the records of the Registrar, at a Redemption Price equal to 100% of the principal amount
of the Securities to be redeemed, plus accrued and unpaid interest to the Redemption Date. 
 In the event of redemption of this Security in
part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof. 

Change of Control. If a Change of Control Triggering Event occurs, unless the Company has exercised its right to redeem
the Securities as described above, it will be required to make an offer to repurchase all, or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof), of each Holder’s Securities pursuant to the offer described below (the
“Change of Control Offer”) on the terms set forth herein. In the Change of Control Offer, the Company will be required to offer payment in cash equal to 101% of the aggregate principal amount of Securities repurchased plus accrued
and unpaid interest, if any, on the Securities repurchased, to the date of repurchase (the “Change of Control Payment”), subject to the rights of Holders of Securities on the relevant record date to receive interest due on the
relevant Interest Payment Date. 
 Within 30 days following any Change of Control Triggering Event or, at the Company’s option,
prior to any Change of Control but after the public announcement of the pending Change of Control, the Company will be required to mail a notice to Holders of Securities describing the 

  
 C-6 

 
transaction or transactions that constitute or may constitute the Change of Control Triggering Event and offering to repurchase the Securities on the date specified in the notice, which date
will be no earlier than 30 days and no later than 60 days from the date such notice is mailed (the “Change of Control Payment Date”), pursuant to the procedures required herein and described in such notice. The Company must comply
with the requirements of Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in
connection with the repurchase of the Securities as a result of a Change of Control Triggering Event. To the extent that the provisions of any securities laws or regulations conflict with the Change of Control provisions herein, the Company will be
required to comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control provisions herein by virtue of such conflicts.  

On the Change of Control Payment Date, the Company will be required, to the extent lawful, to: 

(a) accept for payment all Securities or portions of Securities properly tendered, and not validly withdrawn, pursuant to the Change of
Control Offer; 
 (b) deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Securities or
portions of Securities properly tendered and not validly withdrawn; and 
 (c) deliver or cause to be delivered to the Trustee the
Securities properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Securities or portions of Securities being purchased by the Company. 

The Paying Agent will be required to mail promptly to each Holder who properly tendered Securities the purchase price for such
Securities and the Trustee will be required to authenticate and mail (or cause to be transferred by book entry) promptly to each such Holder a new Security equal in principal amount to any unpurchased portion of the Securities surrendered, if any;
provided that each new Security will be in a principal amount of $2,000 or an integral multiple of $1,000 in excess thereof.  

Notwithstanding the foregoing, the Company will not be required to make a Change of Control Offer with respect to the Securities upon the
occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for such an offer made by the Company and the third party purchases all such
Securities properly tendered and not validly withdrawn under its offer. Further, the Company will not be required to repurchase any Securities if there has occurred and is continuing on the Change of Control Payment Date an Event of Default. 

For purposes of the foregoing discussion of a repurchase at the option of Holders, the following definitions are applicable: 

“Capital Stock” means the capital stock of every class whether now or hereafter authorized, regardless of whether such
capital stock shall be limited to a fixed sum or percentage with respect to the rights of the holders thereof to participate in dividends and in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of
such corporation.  

  
 C-7 

 “Change of Control” means the occurrence of any of the following:

 (a) the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in
one or more series of related transactions, of all or substantially all of the Company’s assets and the assets of its Subsidiaries, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act),
other than the Company or one of its Subsidiaries; 
 (b) the consummation of any transaction (including, without limitation, any merger or
consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than the Company or one of its Subsidiaries, becomes the “beneficial owner” (as defined in Rule
13d-3 under the Exchange Act), directly or indirectly, of more than 50% of the Company’s then outstanding Voting Stock or other Voting Stock into which the Company’s Voting Stock is reclassified, consolidated, exchanged or changed,
measured by voting power rather than number of shares; 
 (c) the Company consolidates, or merges with or into any person, or any person
consolidates with, or merges with or into, the Company, in any such event pursuant to a transaction in which any of its Voting Stock or the Voting Stock of such other person is converted into or exchanged for cash, securities or other property,
other than any such transaction where the shares of the Company’s Voting Stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving person or any
direct or indirect parent company of the surviving person immediately after giving effect to such transaction; 
 (d) the first day on which
a majority of the Company’s members of its board of directors are not Continuing Directors; or 
 (e) the adoption of a plan relating
to the Company’s liquidation or dissolution. 
 Notwithstanding paragraphs (a), (b) and (c) above, a transaction will not be
considered to be a Change of Control if (a) the Company becomes a direct or indirect wholly-owned subsidiary of a holding company and (b)(x) immediately following that transaction, the direct or indirect holders of the Voting Stock of the
holding company are substantially the same as the holders of the Company’s Voting Stock immediately prior to that transaction or (y) immediately following that transaction, no person is the beneficial owner, directly or indirectly, of more
than 50% of the Voting Stock of such holding company. 
 “Change of Control Triggering Event” means the occurrence
of both a Change of Control and a Rating Event. 
 “Continuing Directors” means, as of any date of
determination, any member of the Company’s board of directors who (a) was a member of such board of directors on March 7, 2014 or (b) was nominated for election, elected or appointed to such board of directors with the approval
of a majority of the Continuing Directors who were members of such board of directors at the time of such nomination, election or appointment (either by a specific vote or by approval of a proxy statement in which such member was named as a nominee
for election as a director). 

  
 C-8 

 “Investment Grade” means a rating of Baa3 or better by Moody’s (or
its equivalent under any successor rating categories of Moody’s) and a rating of BBB- or better by S&P (or its equivalent under any successor rating categories of S&P) or the equivalent investment grade credit rating from any additional
Rating Agency or Rating Agencies selected by the Company.  
 “Moody’s” means Moody’s Investors
Service, Inc., a subsidiary of Moody’s Corporation, and its successors.  
 “Rating Agencies” means
(a) each of Moody’s and S&P; and (b) if any of Moody’s or S&P ceases to rate the Securities or fails to make a rating of the Securities publicly available for reasons outside of the Company’s control, a
“nationally recognized statistical rating organization” within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act that is selected by the Company (as certified by a resolution of the Company’s board of directors) as a
replacement agency for Moody’s or S&P, or both of them, as the case may be. 
 “Rating Event” means, with
respect to the Securities, the rating on the Securities is lowered below Investment Grade by each of the Rating Agencies on any date beginning on the date of public notice of an arrangement that could result in a Change of Control until the end of
the 60-day period following public notice of the occurrence of the Change of Control (which 60-day period shall be extended so long as the rating of the Securities is under publicly announced consideration for possible downgrade by any of the Rating
Agencies). 
 “S&P” means Standard & Poor’s Ratings Services, a division of The McGraw-Hill
Companies, Inc., and its successors.  
 “Voting Stock” means, with respect to any specified person as of any
date, the Capital Stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person. 

The Indenture contains provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and
Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture, which provisions apply to this Security. This Security is not subject to repayment at the Holder’s option. 

No reference herein to the Indenture and no provision of this Security or the Indenture shall affect or impair the obligation of the Company,
which is absolute and unconditional, to pay the principal of, premium, if any, and interest on this Security at the respective due dates, place and rate, and in the Currency herein prescribed. 

Default and Remedies. If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of
the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture.  

Amendment, Modification and Waiver. The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the  

  
 C-9 

 
Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority
in principal amount of the Securities at the time outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time
outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by
the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not
notation of such consent or waiver is made upon this Security. 
 Denominations; Transfer and Exchange. As provided in the Indenture
and subject to certain limitations therein set forth, the transfer of this Security is registrable in the records of the Registrar, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place
where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar duly executed by, the Holder hereof or the
Holder’s attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or
transferees.  
 The Securities of this series are issuable only in registered form in denominations of $2,000 and any integral
multiple of $1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor
of a different authorized denomination, as requested by the Holder surrendering the same. 
 No service charge shall be made to a Holder for
any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. 

Persons Deemed Owners. Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent
of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by
notice to the contrary.  
 Miscellaneous. The Indenture and the Securities, including this Security, shall be
governed by and construed in accordance with the laws of the State of New York. 
 All terms used in this Security and not defined
herein shall have the meanings assigned to them in the Indenture. 
 Pursuant to a recommendation promulgated by the Committee on Uniform
Security Identification Procedures, the Company has caused “CUSIP” numbers to be printed on the Securities as a convenience to the Holders of the Securities. No representation is made as to the correctness or accuracy of such CUSIP numbers
as printed on the Securities, and reliance may be placed only on the other identification numbers printed hereon. 

  
 C-10 

 Unless the certificate of authentication hereon has been executed by or on behalf of the Trustee
by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 C-11 

 ASSIGNMENT FORM 

FOR VALUE RECEIVED, the undersigned hereby 

sells, assigns and transfers unto 
 PLEASE INSERT
SOCIAL 
 SECURITY OR OTHER IDENTIFYING 
 NUMBER OF ASSIGNEE

  
  

 
  

(Please Print or Typewrite Name and Address, including Zip Code, of Assignee) 
  

 
 the within Security of Gilead Sciences, Inc. and
                                        
hereby does irrevocably constitute and appoint 
  
  

Attorney to transfer said Security on the books of the within-named Company with full power of substitution in the premises 

 

			
	Dated:	 	  

  

			
	Signature	 	  

 NOTICE: The signature to this assignment must correspond with the name as it appears on the first page of the within Security
in every particular, without alteration or enlargement or any change whatever. 
  

			
	Signature Guaranteed:	 	  

 NOTICE: Signature(s) must be guaranteed by an “eligible guarantor institution” that is a member or
participant in a “signature guarantee program” (e.g., the Securities Transfer Agents Medallion Program, the Stock Exchange Medallion Program and the New York Stock Exchange Medallion Program). 

  
 C-12 

 SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY 

The following increases or decreases in this Global Security have been made: 

 

									
	 Date of

Exchange
	 	 Amount of increase in
Principal Amount of

this Global Security
	 	 Amount of decrease

in Principal Amount
 of this
Global
 Security
	 	 Principal Amount of

this Global Security
 following
such
 decrease or increase
	 	 Signature of

authorized signatory
 of
Trustee

		 		 		 		 	
		 		 		 		 	
		 		 		 		 	
		 		 		 		 	
		 		 		 		 	

  
 C-13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]